NTLA is Intellia Therapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $12.76. Market cap: $1.78B. Capital Quality Rank: 42/100 — Stagnant mediocrity.
Stock snapshot
| Price | $12.76 |
| Market cap | $1.78B |
| Sector | Healthcare |
| Exchange | NGM |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 42 / 100 · Stagnant mediocrity |
| ROIC (TTM) | -67.5% |
| Revenue CAGR (3y) | 9.1% |
| Shareholder buyback yield | -8.79% |
| Altman Z-score zone | Distress |
About NTLA
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Related non-dividend companies
Other non-dividend stocks investors research alongside NTLA. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is NTLA's current stock price?
NTLA (Intellia Therapeutics, Inc.) is currently trading at $12.76.
Does NTLA pay a dividend?
NTLA (Intellia Therapeutics, Inc.) does not currently pay a regular dividend.
What is NTLA's Capital Quality Rank?
NTLA has a Capital Quality Rank of 42/100 — Stagnant mediocrity. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track NTLA in DiviDrip
Add NTLA to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search NTLA and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.